Pharmanutra（PHNM）株式概要Pharmanutra S.p.A.は、医薬品と栄養補助食品の会社で、イタリア、ヨーロッパ、中東、南米、極東、そして国際的に栄養補助食品と医療機器の研究、設計、開発、販売を行っている。 詳細PHNM ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長4/6過去の実績6/6財務の健全性5/6配当金0/6報酬収益は年間19.78%増加すると予測されています 過去1年間で収益は28.1%増加しました リスク分析株式の流動性は非常に低い すべてのリスクチェックを見るPHNM Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€87.900.05% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0235m2016201920222025202620282031Revenue €234.9mEarnings €35.5mAdvancedSet Fair ValueView all narrativesPharmanutra S.p.A. 競合他社Applied NutritionSymbol: LSE:APNMarket cap: UK£746.3mWarpaint LondonSymbol: AIM:W7LMarket cap: UK£174.5mPotter & MooreSymbol: AIM:PAMMarket cap: UK£15.8mUnileverSymbol: LSE:ULVRMarket cap: UK£94.3b価格と性能株価の高値、安値、推移の概要Pharmanutra過去の株価現在の株価€87.9052週高値€87.9052週安値€62.00ベータ0.131ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化40.42%5年間の変化n/aIPOからの変化24.50%最新ニュースBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025最新情報をもっと見るRecent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025お知らせ • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.お知らせ • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024Board Change • Jun 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the United Kingdom.Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (1.8%).Board Change • Apr 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Mar 19Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Personal Products industry in the United Kingdom.Board Change • Feb 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023Board Change • Dec 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Dec 07Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract to acquire Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. As of year ended 2021, Akern s.r.l. reported revenue of €4.2 million, EBITDA of €1.2 million and net income of €0.58 million. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. As of July 26, 2022, Pharmanutra acquired 72.96% stake in Akern from Red Lions. Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri on December 5, 2022.Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 16Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom.Board Change • Aug 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 16Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • May 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Feb 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Feb 15PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel FoodPharmaNutra S.p.A. announced that the European Union had published a notice in the Official Gazette authorising the marketing of cetylated fatty acids as a Novel Food. The novel food (Lipocet®) is a combination of myristic acid and oleic acid and, to a lesser degree, other cetylated fatty acids, which until now could be used only in Cetilar®-branded products for topical use. Consequently, PharmaNutra's patented cetylated fatty acids will be included in the EU list of authorised novel foods established in implementing regulation (EU) 2017/2470. The inclusion of the CFAs in the list marks the official completion of the registration procedure under which, in July 2021, the European Food Safety Authority (EFSA) formalised its positive opinion on the safety of CFAs. The Novel Food authorisation is a fundamental new strategic asset for the Group, as it will enable new nutritional supplements based on CFAs to be developed and marketed. The authorisation also provides a protection for industrial property, giving PharmaNutra exclusive right of use for five-year of the new ingredient throughout the European Union.Board Change • Dec 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.株主還元PHNMGB Personal ProductsGB 市場7D0%-0.8%2.4%1Yn/a-15.5%18.2%株主還元を見る業界別リターン: PHNMがUK Personal Products業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PHNM UK市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PHNM's price volatile compared to industry and market?PHNM volatilityPHNM Average Weekly Movementn/aPersonal Products Industry Average Movement6.3%Market Average Movement5.6%10% most volatile stocks in GB Market11.2%10% least volatile stocks in GB Market3.1%安定した株価: PHNMの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のPHNMのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000140n/awww.pharmanutra.itPharmanutra S.p.A.は製薬・栄養補助食品会社で、イタリア、ヨーロッパ、中東、南米、極東、そして国際的に栄養補助食品と医療機器の研究、設計、開発、販売を行っている。同社は、食品、医薬品、栄養補助食品業界向けに原材料や有効成分を生産・販売している。また、鉄欠乏症、炎症、ミネラル・ビタミン、筋肉・関節、スポーツ栄養、眼科、ナイトレスト製品、生体インピーダンス分析用医療機器・ソフトウェアも提供している。同社は、販売代理店、卸売業者、薬局、準薬局、代理店、ディストリビューター、オンライン販売、地域パートナー、入札を通じて製品を販売している。Pharmanutra S.p.A.は2003年に設立され、イタリアのピサに本社を置いている。もっと見るPharmanutra S.p.A. 基礎のまとめPharmanutra の収益と売上を時価総額と比較するとどうか。PHNM 基礎統計学時価総額€856.02m収益（TTM）€21.02m売上高(TTM)€138.94m40.7xPER（株価収益率6.2xP/SレシオPHNM は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PHNM 損益計算書（TTM）収益€138.94m売上原価€68.31m売上総利益€70.63mその他の費用€49.61m収益€21.02m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）2.20グロス・マージン50.83%純利益率15.13%有利子負債／自己資本比率23.5%PHNM の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.3%現在の配当利回り55%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 21:48終値2026/05/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmanutra S.p.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Anna FrontaniBerenbergAndrea RandoneIntermonte SIM S.p.A.Giorgio TavoliniIntermonte SIM S.p.A.3 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.
お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 30Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
お知らせ • Mar 19Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time.
お知らせ • Mar 18Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025.
お知らせ • Mar 06Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Dec 18+ 1 more updatePharmanutra S.p.A. to Report Fiscal Year 2024 Results on Mar 14, 2025Pharmanutra S.p.A. announced that they will report fiscal year 2024 results on Mar 14, 2025
お知らせ • Jan 14Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023.
お知らせ • Jan 13Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024
Board Change • Jun 02Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 18First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €24.6m (up 30% from 1Q 2022). Net income: €5.43m (up 56% from 1Q 2022). Profit margin: 22% (up from 19% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Personal Products industry in the United Kingdom.
Upcoming Dividend • May 01Upcoming dividend of €0.80 per share at 1.6% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 10 May 2023. Payout ratio is a comfortable 51% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (1.8%).
Board Change • Apr 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 11Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 19Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)Full year 2022 results: EPS: €1.56 (up from €1.42 in FY 2021). Revenue: €83.4m (up 22% from FY 2021). Net income: €15.0m (up 9.3% from FY 2021). Profit margin: 18% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Personal Products industry in the United Kingdom.
Board Change • Feb 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jan 13+ 2 more updatesPharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023Pharmanutra S.p.A. announced that they will report fiscal year 2022 results on Mar 16, 2023
Board Change • Dec 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Dec 07Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract to acquire Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. As of year ended 2021, Akern s.r.l. reported revenue of €4.2 million, EBITDA of €1.2 million and net income of €0.58 million. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity. As of July 26, 2022, Pharmanutra acquired 72.96% stake in Akern from Red Lions. Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri on December 5, 2022.
Board Change • Oct 14Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 16Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)Second quarter 2022 results: EPS: €0.49 (up from €0.47 in 2Q 2021). Revenue: €21.1m (up 17% from 2Q 2021). Net income: €4.75m (up 4.7% from 2Q 2021). Profit margin: 23% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom.
Board Change • Aug 04Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 16Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million on June 15, 2022. The acquisition price of €15 million, including €3 million linked to EBITDA and gross margin targets for the years 2022, 2023, and 2024. The closing is subject, among others, to the “Golden Power” authorization by the Italian government and it will be completed with two separate operations: by July 2022 there will be the purchase of the stake of Red Lions and Jacopo Talluri, representing respectively 72.96% and 13.52% of Akern’s equity; by December 2022 there will be the purchase of the stake of Liside, 13.52% of Akern’s equity.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • May 17Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 01Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Feb 24Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Feb 15PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel FoodPharmaNutra S.p.A. announced that the European Union had published a notice in the Official Gazette authorising the marketing of cetylated fatty acids as a Novel Food. The novel food (Lipocet®) is a combination of myristic acid and oleic acid and, to a lesser degree, other cetylated fatty acids, which until now could be used only in Cetilar®-branded products for topical use. Consequently, PharmaNutra's patented cetylated fatty acids will be included in the EU list of authorised novel foods established in implementing regulation (EU) 2017/2470. The inclusion of the CFAs in the list marks the official completion of the registration procedure under which, in July 2021, the European Food Safety Authority (EFSA) formalised its positive opinion on the safety of CFAs. The Novel Food authorisation is a fundamental new strategic asset for the Group, as it will enable new nutritional supplements based on CFAs to be developed and marketed. The authorisation also provides a protection for industrial property, giving PharmaNutra exclusive right of use for five-year of the new ingredient throughout the European Union.
Board Change • Dec 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Chairman of the Board of Statutory Auditors Michele Lorenzini was the last director to join the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
